SAB Biotherapeutics, Inc. (SABSW) stock
SABSWNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as SABS
$0.01+0.00 (+33.33%)
Close on Oct 20, 2026Market cap $304.80MP/E –Yield –
SAB Biotherapeutics revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
SAB Biotherapeutics's revenue for the twelve months ending Dec 31, 2024 was $1.32M, down 40.9% year over year. For fiscal 2025 it was $0, down 100.0% from the year before. The highest annual figure on record is $60.88M in fiscal 2021.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $0 | -100.0% |
| FY2024 | Dec 31, 2024 | $1.32M | -40.9% |
| FY2023 | Dec 31, 2023 | $2.24M | -90.6% |
| FY2022 | Dec 31, 2022 | $23.90M | -60.7% |
| FY2021 | Dec 31, 2021 | $60.88M | +10.2% |
| FY2020 | Dec 31, 2020 | $55.24M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2024 | Dec 31, 2024 | $114.70K | -62.4% |
| Q3 FY2024 | Sep 30, 2024 | $0 | -100.0% |
| Q2 FY2024 | Jun 30, 2024 | $263.14K | +207.7% |
| Q1 FY2024 | Mar 31, 2024 | $944.58K | +62.5% |
| Q4 FY2023 | Dec 31, 2023 | $305.01K | -85.9% |
| Q3 FY2023 | Sep 30, 2023 | $1.27M | -64.7% |
| Q2 FY2023 | Jun 30, 2023 | $85.52K | -98.7% |
| Q1 FY2023 | Mar 31, 2023 | $581.10K | -95.1% |
| Q4 FY2022 | Dec 31, 2022 | $2.16M | -80.5% |
| Q3 FY2022 | Sep 30, 2022 | $3.59M | -75.5% |
| Q2 FY2022 | Jun 30, 2022 | $6.35M | -65.1% |
| Q1 FY2022 | Mar 31, 2022 | $11.80M | -30.3% |
| Q4 FY2021 | Dec 31, 2021 | $11.06M | – |
| Q3 FY2021 | Sep 30, 2021 | $14.68M | – |
| Q2 FY2021 | Jun 30, 2021 | $18.21M | – |
| Q1 FY2021 | Mar 31, 2021 | $16.93M | – |